Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03442569
Title PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
Indiana University Health Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27509 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
University of Washington - Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field